This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (47)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

The Importance of Reporting Suspected Reactions

Diane K. Wysowski, PhD; Lynette Swartz, MEd, MBA

Arch Intern Med. 2005;165:1363-1369.

Background  The Adverse Event Reporting System is the primary surveillance database used by the Food and Drug Administration for identifying postmarketing drug safety problems.

Methods  We analyzed all reports of suspected adverse drug reactions submitted to the Food and Drug Administration from the inception of the Adverse Event Reporting System database in 1969 through December 2002. We documented drug withdrawals and restricted distribution programs based on safety concerns.

Results  During the 33-year period from 1969 when adverse drug event reporting was initiated through 2002, about 2.3 million case reports of adverse events for the cumulative number of approximately 6000 marketed drugs were entered in the database. Most reports were for female patients. During this period, numerous drug reactions have been identified and added to the product labeling as boxed warnings, warnings, precautions, contraindications, and adverse reactions. More than 75 drugs/drug products have been removed from the market due to safety problems. In addition, 11 drugs have special requirements for prescriptions or have restricted distribution programs. Drugs withdrawn or restricted represent a small proportion (about 1%) of marketed drugs.

Conclusions  The Food and Drug Administration’s Adverse Event Reporting System is the primary surveillance database used for the identification of safety problems of marketed drugs. Despite the limitations of underreporting, differential reporting, and uneven quality, submitted reports often allow the identification of serious adverse events that are added to the product labeling information. In rare instances, additional regulations, up to and including market removal, have been required. We encourage physicians, pharmacists, other health care professionals, and patients to continue to report serious suspected and known adverse drug reactions to manufacturers and the Food and Drug Administration.

Author Affiliations: Office of Drug Safety, Food and Drug Administration, Rockville, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Toxicity Testing in the 21st Century: A View from the Pharmaceutical Industry
MacDonald and Robertson
Toxicol Sci 2009;110:40-46.
FULL TEXT  

When I Use a word ... Changing your practice
Aronson
QJM 2009;0:hcp055v1-hcp055.
FULL TEXT  

Active Computerized Pharmacovigilance Using Natural Language Processing, Statistics, and Electronic Health Records: A Feasibility Study
Wang et al.
J. Am. Med. Inform. Assoc. 2009;16:328-337.
ABSTRACT | FULL TEXT  

Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity
Smith et al.
Pediatrics 2008;122:e628-e633.
ABSTRACT | FULL TEXT  

Use Of Larger Versus Smaller Drug-Safety Databases Before Regulatory Approval: The Trade-Offs
Reed et al.
Health Aff (Millwood) 2008;27:w360-w370.
ABSTRACT | FULL TEXT  

Effects of Cerivastatin Withdrawal on Statin Persistence
Reaume et al.
The Annals of Pharmacotherapy 2008;42:956-961.
ABSTRACT | FULL TEXT  

Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective
Tremlett and Oger
Mult Scler 2008;14:94-105.
ABSTRACT  

Using population-based routine data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK and the USA
Morrato et al.
J Public Health (Oxf) 2007;29:463-471.
ABSTRACT | FULL TEXT  

Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action
Wysowski et al.
Arch Intern Med 2007;167:1414-1419.
ABSTRACT | FULL TEXT  

POSTMARKETING MODIFICATIONS IN THE SAFETY LABELING OF THE NEW ANTIEPILEPTICS
Buck et al.
Neurology 2007;68:1536-1537.
FULL TEXT  

The FDA and drug safety: a proposal for sweeping changes.
Furberg et al.
Arch Intern Med 2006;166:1938-1942.
ABSTRACT | FULL TEXT  

An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial.
Figueiras et al.
JAMA 2006;296:1086-1093.
ABSTRACT | FULL TEXT  

Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch
Smith et al.
Am J Health Syst Pharm 2006;63:949-952.
FULL TEXT  

Clinical Trials in the Wake of Vioxx: Requiring Statistically Extreme Evidence of Benefit to Ensure the Safety of New Drugs
Roth-Cline
Circulation 2006;113:2253-2259.
FULL TEXT  

Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
Qureshi and Fischer
Arch Dermatol 2006;142:633-637.
FULL TEXT  

Allergic Reactions After the Implantation of Drug-Eluting Stents: Is it the Pill or the Polymer?
Azarbal and Currier
J Am Coll Cardiol 2006;47:182-183.
FULL TEXT